Published in Pharmacol Rev on August 10, 2012
Inflammation in the pathogenesis of microvascular complications in diabetes. Front Endocrinol (Lausanne) (2012) 1.24
Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on these targets. Int J Endocrinol (2014) 1.09
Mesenchymal stem cell-based treatment for microvascular and secondary complications of diabetes mellitus. Front Endocrinol (Lausanne) (2014) 0.90
Tests for early diagnosis of cardiovascular autonomic neuropathy: critical analysis and relevance. Front Endocrinol (Lausanne) (2013) 0.88
Heat shock protein 70 is necessary to improve mitochondrial bioenergetics and reverse diabetic sensory neuropathy following KU-32 therapy. J Pharmacol Exp Ther (2013) 0.87
Na+/H+ exchanger 1 inhibition reverses manifestation of peripheral diabetic neuropathy in type 1 diabetic rats. Am J Physiol Endocrinol Metab (2013) 0.83
Induction of heat shock protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun. ASN Neuro (2012) 0.81
Modulating Molecular Chaperones Improves Mitochondrial Bioenergetics and Decreases the Inflammatory Transcriptome in Diabetic Sensory Neurons. ACS Chem Neurosci (2015) 0.79
Antioxidation and anti-inflammatory activity of Tang Bi Kang in rats with diabetic peripheral neuropathy. BMC Complement Altern Med (2015) 0.79
Diabetic neuropathy and the sensory apparatus "meissner corpuscle and merkel cells". Front Neuroanat (2014) 0.75
Thymoquinone Alleviates the Experimental Diabetic Peripheral Neuropathy by Modulation of Inflammation. Sci Rep (2016) 0.75
Promoting Neuronal Tolerance of Diabetic Stress: Modulating Molecular Chaperones. Int Rev Neurobiol (2016) 0.75
Mesenchymal stem cells to treat diabetic neuropathy: a long and strenuous way from bench to the clinic. Cell Death Discov (2016) 0.75
Neurotoxic effects of iron overload under high glucose concentration. Neural Regen Res (2013) 0.75
Angiogenin gene polymorphism: A risk factor for diabetic peripheral neuropathy in the northern Chinese Han population. Neural Regen Res (2013) 0.75
Targeting the Diabetic Chaperome to Improve Peripheral Neuropathy. Curr Diab Rep (2016) 0.75
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract (2009) 25.83
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature (2000) 12.33
Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci (2005) 9.75
Molecular mechanisms of nociception. Nature (2001) 7.75
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature (2003) 7.69
Vascular risk factors and diabetic neuropathy. N Engl J Med (2005) 7.69
Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ (2006) 6.12
Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA (1998) 5.91
Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci (2005) 5.00
Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem (2011) 4.95
Molecular chaperones Hsp90 and Hsp70 deliver preproteins to the mitochondrial import receptor Tom70. Cell (2003) 4.46
The evidence for pharmacological treatment of neuropathic pain. Pain (2010) 4.35
Neuregulin-1 type III determines the ensheathment fate of axons. Neuron (2005) 4.19
Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem (1991) 4.16
Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care (2006) 3.47
Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest (2001) 3.46
Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A (2000) 3.36
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest (2007) 3.35
17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med (2005) 3.19
Bioenergetic analysis of isolated cerebrocortical nerve terminals on a microgram scale: spare respiratory capacity and stochastic mitochondrial failure. J Neurochem (2009) 2.92
Recruitment of O-GlcNAc transferase to promoters by corepressor mSin3A: coupling protein O-GlcNAcylation to transcriptional repression. Cell (2002) 2.89
Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res (2010) 2.87
Mitochondrial protein import: from proteomics to functional mechanisms. Nat Rev Mol Cell Biol (2010) 2.87
Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev (2004) 2.83
Axonal regulation of myelination by neuregulin 1. Curr Opin Neurobiol (2006) 2.78
17AAG: low target binding affinity and potent cell activity--finding an explanation. Mol Cancer Ther (2003) 2.74
A central role for the ERK-signaling pathway in controlling Schwann cell plasticity and peripheral nerve regeneration in vivo. Neuron (2012) 2.72
Diet and exercise among adults with type 2 diabetes: findings from the third national health and nutrition examination survey (NHANES III). Diabetes Care (2002) 2.64
The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem (2000) 2.62
Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology (2003) 2.62
Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest (2003) 2.60
Diabetic neuropathy: mechanisms to management. Pharmacol Ther (2008) 2.57
Hot-tub therapy for type 2 diabetes mellitus. N Engl J Med (1999) 2.52
HSP72 protects against obesity-induced insulin resistance. Proc Natl Acad Sci U S A (2008) 2.52
Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med (2008) 2.44
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
Clinical practice. Painful sensory neuropathy. N Engl J Med (2003) 2.40
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology (2006) 2.39
Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res (2002) 2.37
Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain (2004) 2.32
Glucose neurotoxicity. Nat Rev Neurosci (2008) 2.32
Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity. Diabetes Care (2007) 2.29
Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care (2006) 2.25
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett (2007) 2.21
Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology (1998) 2.17
Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol (2008) 2.15
The Ras/Raf/ERK signalling pathway drives Schwann cell dedifferentiation. EMBO J (2004) 2.15
Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal (2010) 2.11
Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst (2000) 2.09
Diabetic neuropathy: an intensive review. Am J Health Syst Pharm (2004) 2.06
Chemical manipulation of hsp70 ATPase activity regulates tau stability. J Neurosci (2009) 2.05
Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes (2009) 1.99
A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med (2005) 1.99
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest (2004) 1.92
The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain (2004) 1.90
High-fat diet induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition. Diabetes (2007) 1.85
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol (2003) 1.85
Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain (2003) 1.85
Proteomic alterations of distinct mitochondrial subpopulations in the type 1 diabetic heart: contribution of protein import dysfunction. Am J Physiol Regul Integr Comp Physiol (2010) 1.84
The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications (2012) 1.79
Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes (2004) 1.79
Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci U S A (2007) 1.77
Insulin signaling meets mitochondria in metabolism. Trends Endocrinol Metab (2010) 1.77
GDNF rescues hyperglycemia-induced diabetic enteric neuropathy through activation of the PI3K/Akt pathway. J Clin Invest (2006) 1.77
Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics (2009) 1.75
Axonal interactions regulate Schwann cell apoptosis in developing peripheral nerve: neuregulin receptors and the role of neuregulins. J Neurosci (1996) 1.71
Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nat Rev Drug Discov (2011) 1.71
Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care (2011) 1.70
ANTI-HSP60 and ANTI-HSP70 antibody levels and micro/ macrovascular complications in type 1 diabetes: the EURODIAB Study. J Intern Med (2009) 1.68
Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. Cell Metab (2012) 1.66
Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications (2006) 1.66
Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res (1990) 1.65
Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidative-nitrosative stress and p38 MAPK activation. Exp Neurol (2011) 1.65
Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes (2009) 1.64
Small-molecule proteostasis regulators for protein conformational diseases. Nat Chem Biol (2011) 1.64
Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia (2005) 1.64
O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc Natl Acad Sci U S A (2001) 1.60
Modulating molecular chaperones improves sensory fiber recovery and mitochondrial function in diabetic peripheral neuropathy. Exp Neurol (2012) 1.59
Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev (2006) 1.58
Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. Diabetes (1988) 1.52
Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst (2009) 1.52
Glial growth factor/neuregulin inhibits Schwann cell myelination and induces demyelination. J Cell Biol (2001) 1.51
Hsp90: a novel target for the disruption of multiple signaling cascades. Curr Cancer Drug Targets (2007) 1.51
Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. Diabetes (2003) 1.50
Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited. Diabetes (2005) 1.50
Bimoclomol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects. Nat Med (1997) 1.50
Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev (2011) 1.50
Diabetic neuropathy and nerve regeneration. Prog Neurobiol (2003) 1.49
Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain (2007) 1.49
Microanatomy of axon/glial signaling during Wallerian degeneration. J Neurosci (2005) 1.46
Glyoxalase in diabetes, obesity and related disorders. Semin Cell Dev Biol (2011) 1.46
Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction. Diabetes (2000) 1.45
Bioenergetic function in cardiovascular cells: the importance of the reserve capacity and its biological regulation. Chem Biol Interact (2010) 1.45
Retracted Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes (2007) 1.44
Bioenergetics of mitochondria in cultured neurons and their role in glutamate excitotoxicity. J Neurosci Res (2007) 1.44
Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology (2006) 1.44
A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem (2003) 2.69
Modulating molecular chaperones improves sensory fiber recovery and mitochondrial function in diabetic peripheral neuropathy. Exp Neurol (2012) 1.59
Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice. ASN Neuro (2010) 1.21
Ceramide displaces cholesterol from lipid rafts and decreases the association of the cholesterol binding protein caveolin-1. J Lipid Res (2005) 1.21
Diminished superoxide generation is associated with respiratory chain dysfunction and changes in the mitochondrial proteome of sensory neurons from diabetic rats. Diabetes (2010) 1.18
Hyperglycemia alters the schwann cell mitochondrial proteome and decreases coupled respiration in the absence of superoxide production. J Proteome Res (2010) 1.08
Hyperglycemia and downregulation of caveolin-1 enhance neuregulin-induced demyelination. Glia (2008) 0.98
Caveolin-1 and altered neuregulin signaling contribute to the pathophysiological progression of diabetic peripheral neuropathy. Diabetes (2009) 0.98
Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons. J Neurochem (2003) 0.98
Nutrient excess and altered mitochondrial proteome and function contribute to neurodegeneration in diabetes. Mitochondrion (2011) 0.96
C-terminal heat shock protein 90 inhibitor decreases hyperglycemia-induced oxidative stress and improves mitochondrial bioenergetics in sensory neurons. J Proteome Res (2012) 0.96
Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis. Cancer Res (2005) 0.96
Tau neurofibrillary pathology and microtubule stability. J Mol Neurosci (2002) 0.88
Heat shock protein 70 is necessary to improve mitochondrial bioenergetics and reverse diabetic sensory neuropathy following KU-32 therapy. J Pharmacol Exp Ther (2013) 0.87
Fluorogenic Tagging of Peptide and Protein 3-Nitrotyrosine with 4-(Aminomethyl)-benzenesulfonic Acid for Quantitative Analysis of Protein Tyrosine Nitration. Chromatographia (2010) 0.87
Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity. J Med Chem (2012) 0.86
Dopamine D(2) receptor function is compromised in the brain of the methionine sulfoxide reductase A knockout mouse. J Neurochem (2010) 0.84
Decreased activity and enhanced nuclear export of CCAAT-enhancer-binding protein beta during inhibition of adipogenesis by ceramide. Biochem J (2002) 0.83
Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90α/Aha1 complex in PC3-MM2 cells. ACS Chem Biol (2014) 0.83
Induction of heat shock protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun. ASN Neuro (2012) 0.81
Nerve growth factor blocks the glucose-induced down-regulation of caveolin-1 expression in Schwann cells via p75 neurotrophin receptor signaling. J Biol Chem (2003) 0.80
Role of a cdk5-associated protein, p35, in herpes simplex virus type 1 replication in vivo. J Neurovirol (2010) 0.78
p35/Cyclin-dependent kinase 5 is required for protection against beta-amyloid-induced cell death but not tau phosphorylation by ceramide. J Mol Neurosci (2007) 0.77
Differential expression of neuregulin-1 isoforms and downregulation of erbin are associated with Erb B2 receptor activation in diabetic peripheral neuropathy. Acta Neuropathol Commun (2013) 0.75
Heat shock response and insulin-associated neurodegeneration. Trends Pharmacol Sci (2011) 0.75
Formation of new stellar populations from gas accreted by massive young star clusters. Nature (2016) 0.75